Walleye Capital’s Alpine Immune Sciences Inc ALPN Stock Holding History

Walleye Capital’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-206,104	Closed	-$8.17M	–	6172
2024 Q1	$8.17M	Sell	206,104 -159,836	-44%	-$4.72M	0.01%	961
2023 Q4	$6.97M	Buy	365,940 +179,667	+96%	+$2.5M	0.01%	885
2023 Q3	$2.13M	Buy	186,273 +21,600	+13%	+$266K	0.01%	1684
2023 Q2	$1.69M	Buy	164,673 +130,556	+383%	+$1.18M	0.01%	1445
2023 Q1	$263K	Buy	+34,117	New	+$272K	﹤0.01%	2231
2022 Q4	–	Sell	-71,355	Closed	-$514K	–	3749
2022 Q3	$514K	Buy	+71,355	New	+$588K	0.01%	1442
2022 Q2	–	Sell	-41,746	Closed	-$374K	–	2783
2022 Q1	$374K	Sell	41,746 -68,353	-62%	-$591K	0.01%	1175
2021 Q4	$1.52M	Buy	+110,099	New	+$1.36M	0.05%	400

Walleye Capital's ALPN Position: Q2 2024 in Review

Walleye Capital sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 206,104 shares — an estimated $8.17M sold.

Walleye Capital first reported a position in ALPN in Q4 2021 and held it in 8 quarters. The position peaked at $8.17M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

Walleye Capital reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
Walleye Capital sold 206,104 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $8.17M.
Walleye Capital first reported a position in Alpine Immune Sciences Inc in Q4 2021 and held it in 8 quarters.
Walleye Capital's Alpine Immune Sciences Inc position peaked at $8.17M in Q1 2024.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.